<DOC>
	<DOCNO>NCT01733290</DOCNO>
	<brief_summary>This study design aim determine clinical efficacy BoNT-A patient dysfunctional voiding . The result study provide information patient selection therapeutic duration .</brief_summary>
	<brief_title>Botulinum Toxin Urethral Sphincter Injection Dysfunctional Voiding</brief_title>
	<detailed_description>This study design randomize , double-blind , placebo control , multicentric trial . A total 60 patient enrol . All patient suffer dysfunctional void refractory conventional treatment . The enrolled patient severe dysuria urinary retention , large residual urine treat medication therapeutic modality 3 month . The patient randomly assign allocate treatment control group 2:1 ratio . About 40 20 patient enrolled treatment control group , respectively . This study approve Institutional Review Board ( IRB ) ethical committee hospital . Every patient thoroughly inform write informed consent obtain treatment . Patients receive complete urological work-up treatment , include urinalysis , urine culture , cystoscopy prove anatomical stricture lower urinary tract pathology , videourodynamic study . All medication may affect low urinary tract function stop least 1 week Botulinum Toxin A ( BoNT-A ) injection . Videourodynamic study perform patient supine position patient stand sit commode . A 6 Fr dual channel urethral pressure profile ( UPP ) urethral catheter insert urinary bladder . After evacuation residual urine , urethral pressure profilometry perform first . Then bladder fill normal saline contain 20 % urografin filling rate 30 ml/min . The fill voiding cystourethrography investigate C-arm position patient . Uroflowmetry record weighed transducer place examination table . After bladder fill capacity , patient ask urinate per urethra . If patient urinate per urethrae urethral catheter situ , suprapubic puncture 18 Gauge needle 3-Fr epidural catheter undertaken patient urinate without catheter urethra . The patient request stand urinate commode . Pressure flow study concomitant void cystourethrography perform . The urodynamic parameter include maximal urethral closure pressure ( MUCP ) , functional profile length ( FPL ) , cystometric bladder capacity ( CBC ) , bladder compliance , void detrusor pressure ( Pdet ) , maximal flow rate ( Qmax ) , voided volume , postvoid residual urine volume ( PVR ) . In patient detrusor underactivity , abdominal pressure urinate detrusor leak point pressure measure . Images void cystourethrography emphasize bladder neck opening , urethral sphincter relaxation , dilatation posterior urethra voiding . Patients admit BoNT-A ( treatment group ) normal saline ( control group ) injection perform operation room complete cardiovascular monitoring available operation . BoNT-A injection make cystoscopy guide male patient inject periurethrally female patient . The BoNT-A purchase Allergan Company ( Botox , 100 units/vial , Irvine , California , U.S.A. ) . Each vial BoNT-A dilute 5 ml normal saline . A total 100 unit BoNT-A inject deeply external sphincter 3 , 6 , 9 12 o'clock position approximate equal aliquot . After BoNT-A injection , 14 Fr Foley catheter indwell routinely 1 day remove . Patients follow voiding condition . When dysuria persist , intermittent catheterization advise instead indwell Foley catheter . Antibiotics necessary unless urinary tract infection occur , medication reduce urethral sphincteric resistance discontinue . Patients closely contact monitor research assistant telephone . They follow out-patient clinic 1 week , 2 week 4 week BoNT-A injection . After first month initial BoNT-A injection , patient follow monthly therapeutic effect go . Videourodynamic study UPP study perform 4 week BoNT-A injection . The subjective improvement void condition assess obstructive symptom score ( include hesitancy , intermittency , dysuria , small caliber urine ) quality life score adopt International Prostate Symptom Score ( IPSS ) system . The primary end-point change Patient Perception Bladder Condition ( PPBC ) 4 week initial injection . If patient PPBC improve two scale , consider successfully treat , otherwise fail treatment . The subjective symptom score , quality life score urodynamic parameter compare baseline 4 week BoNT-A injection within treatment group control group . For patient significant improvement 4 week BoNT-A injection , second injection 100 unit BoNT-A perform 4 week initial injection regardless patient 's initial grouping . These patient follow interval return void dysfunction . Continuous variable present mean Â± standard deviation ( SDs ) , categorical data present number percentage ( % ) . Statistical comparison within group perform paired test , group test use chi-square test categorical variable , Wilcoxon rank-sum test continuous variable . Long-term successful result compare use Kaplan-Meier analysis . Statistical assessment consider significant p &lt; 0.05 . Statistical analysis perform use SPSS 15.0 statistical software ( SPSS Inc. , Chicago , IL ) . Any side effect relate BoNT-A injection ask report . There report serious side effect local injection BoNT-A urethral sphincter . However , potential side effect , exacerbation urinary incontinence , allergy anaphylactic shock inform patient carefully monitor postoperative condition . Urinalysis check first follow-up 1 2 week BoNT-A injection . Antibiotics give patient significant urinary tract infection .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adults age 20 year old . Free active urinary tract infection . Free bladder outlet obstruction enrollment . Patients severe dysuria urinary retention , large residual urine treat medication therapeutic modality 3 month . Patients severe cardiopulmonary disease congestive heart failure , arrhythmia , poorly control hypertension , able receive regular followup . Patients bladder outlet obstruction enrollment . Patients uncontrolled confirmed diagnosis acute urinary tract infection . Patients laboratory abnormality screen include : Alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal range aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range . Patients abnormal serum creatinine level &gt; 2 x upper limit normal range . Patients contraindication urethral catheterization treatment . Female patient pregnant , lactating , childbearing potential without contraception . Patients serious disease consider investigator suitable general anesthesia condition enter trial . Patients participate investigational drug trial within 1 month enter study . Written inform consent obtain .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Botulinum Toxin A ( BoNT-A )</keyword>
	<keyword>Dysfunctional voiding</keyword>
</DOC>